Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.

Santin AD, Vergote I, González-Martín A, Moore K, Oaknin A, Romero I, Diab S, Copeland LJ, Monk BJ, Coleman RL, Herzog TJ, Siegel J, Kasten L, Schlicker A, Schulz A, Köchert K, Walter AO, Childs BH, Elbi C, Bulat I.

Open source

DOI: 10.1136/ijgc-2022-003927
Published: 2023-04-03
Container: Int J Gynecol Cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/ijgc-2022-003927,
  title = {Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.},
  author = {Santin AD and  Vergote I and  González-Martín A and  Moore K and  Oaknin A and  Romero I and  Diab S and  Copeland LJ and  Monk BJ and  Coleman RL and  Herzog TJ and  Siegel J and  Kasten L and  Schlicker A and  Schulz A and  Köchert K and  Walter AO and  Childs BH and  Elbi C and  Bulat I.},
  year = {2023},
  journal = {Int J Gynecol Cancer},
  doi = {10.1136/ijgc-2022-003927},
  url = {https://doi.org/10.1136/ijgc-2022-003927}
}

RIS

TY  - JOUR
TI  - Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
AU  - Santin AD
AU  -  Vergote I
AU  -  González-Martín A
AU  -  Moore K
AU  -  Oaknin A
AU  -  Romero I
AU  -  Diab S
AU  -  Copeland LJ
AU  -  Monk BJ
AU  -  Coleman RL
AU  -  Herzog TJ
AU  -  Siegel J
AU  -  Kasten L
AU  -  Schlicker A
AU  -  Schulz A
AU  -  Köchert K
AU  -  Walter AO
AU  -  Childs BH
AU  -  Elbi C
AU  -  Bulat I.
PY  - 2023
JO  - Int J Gynecol Cancer
DO  - 10.1136/ijgc-2022-003927
UR  - https://doi.org/10.1136/ijgc-2022-003927
ER  -

APA

AD, S., I, V., A, G., K, M., A, O., I, R., S, D., LJ, C., BJ, M., RL, C., TJ, H., J, S., L, K., A, S., A, S., K, K., AO, W., BH, C., C, E., & I., B. (2023). Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.. Int J Gynecol Cancer. https://doi.org/10.1136/ijgc-2022-003927

Source records

europe-pmc · retrieved 2026-09-26T18:04:11.189Z